image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 73.3
0.383 %
$ 14.6 B
Market Cap
35.41
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one COO stock under the worst case scenario is HIDDEN Compared to the current market price of 73.3 USD, The Cooper Companies, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one COO stock under the base case scenario is HIDDEN Compared to the current market price of 73.3 USD, The Cooper Companies, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one COO stock under the best case scenario is HIDDEN Compared to the current market price of 73.3 USD, The Cooper Companies, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart COO

image
$100.0$100.0$95.0$95.0$90.0$90.0$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
3.9 B REVENUE
8.41%
706 M OPERATING INCOME
32.38%
392 M NET INCOME
33.34%
709 M OPERATING CASH FLOW
16.76%
-765 M INVESTING CASH FLOW
-70.29%
39.2 M FINANCING CASH FLOW
122.54%
1 B REVENUE
3.90%
185 M OPERATING INCOME
1.54%
87.7 M NET INCOME
-15.92%
96.2 M OPERATING CASH FLOW
-49.53%
-79.2 M INVESTING CASH FLOW
18.18%
-8.6 M FINANCING CASH FLOW
91.10%
Balance Sheet The Cooper Companies, Inc.
image
Current Assets 1.95 B
Cash & Short-Term Investments 108 M
Receivables 717 M
Other Current Assets 1.13 B
Non-Current Assets 10.4 B
Long-Term Investments 0
PP&E 1.86 B
Other Non-Current Assets 8.5 B
5.82 %9.15 %15.13 %69.02 %Total Assets$12.3b
Current Liabilities 1.02 B
Accounts Payable 260 M
Short-Term Debt 33.3 M
Other Current Liabilities 729 M
Non-Current Liabilities 3.21 B
Long-Term Debt 2.55 B
Other Non-Current Liabilities 658 M
6.16 %17.23 %60.27 %15.56 %Total Liabilities$4.2b
EFFICIENCY
Earnings Waterfall The Cooper Companies, Inc.
image
Revenue 3.9 B
Cost Of Revenue 1.3 B
Gross Profit 2.6 B
Operating Expenses 1.89 B
Operating Income 706 M
Other Expenses 313 M
Net Income 392 M
4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(1b)3b(2b)706m(313m)392mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
66.64% GROSS MARGIN
66.64%
18.12% OPERATING MARGIN
18.12%
10.07% NET MARGIN
10.07%
4.85% ROE
4.85%
3.19% ROA
3.19%
4.20% ROIC
4.20%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis The Cooper Companies, Inc.
image
600m600m500m500m400m400m300m300m200m200m100m100m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 392 M
Depreciation & Amortization 375 M
Capital Expenditures -421 M
Stock-Based Compensation 75.1 M
Change in Working Capital -334 M
Others -85 M
Free Cash Flow 288 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets The Cooper Companies, Inc.
image
Wall Street analysts predict an average 1-year price target for COO of $104 , with forecasts ranging from a low of $94 to a high of $115 .
COO Lowest Price Target Wall Street Target
94 USD 28.24%
COO Average Price Target Wall Street Target
104 USD 42.16%
COO Highest Price Target Wall Street Target
115 USD 56.89%
Price
Max Price Target
Min Price Target
Average Price Target
1151151101101051051001009595909085858080757570706565Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.0075 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.01600.01600.01400.01400.01200.01200.01000.01000.00800.00800.00600.00600.00400.00400.00200.00200.00000.00000.00750.00750.00750.00750.00750.00750.00750.00750.00750.00750.020.00750.020.00750.020.00750.020.00750.020.00750.020.00750.020.00750.020.00750.02201520152016201620172017201820182019201920202020202120212022202220232023
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership The Cooper Companies, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
27.6 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
COO Stock Declines Despite Strong Core Growth Amid Fertility Woes The Cooper Companies grows margins and premium products, but fertility softness, inventory cuts, and tariffs weigh on the near-term outlook. zacks.com - 1 week ago
HOLX vs. COO: Which GYN Surgical Stock Is the Better Investment Now? As demand for GYN surgical tools climbs, HOLX and COO battle it out. Find out which stock shows stronger growth momentum now. zacks.com - 3 weeks ago
Medicus Pharma names Andrew Smith as COO, advances BCC and prostate drug studies Medicus Pharma (NASDAQ:MDCX) said on Monday it has appointed Andrew Smith as chief operating officer, bringing on board a seasoned asset management executive as the company accelerates its clinical development programs in the US, Europe, and the Middle East. Smith, who most recently served as CEO of SR Asset Management until its sale in 2024, brings over 30 years of experience in financial and operational leadership. proactiveinvestors.com - 3 weeks ago
Lockheed Martin COO on Trump's Golden Dome: Three-year timeline is 'very realistic' Lockheed Martin COO Frank St. John said Monday that a timeline of three to four years for building President Donald Trump's Golden Dome defense plan is "very realistic." youtube.com - 4 weeks ago
Lockheed Martin COO: We are probably at the beginning of a 3-to-5-year surge in defense spending CNBC's Phil LeBeau talks to Lockheed Martin COO Frank St. John  to discuss the state of defense spending, whether 'Golden Dome' actually works, and more. youtube.com - 4 weeks ago
3 Oversold Stocks Flashing Bullish Reversal Signals When it comes to short-term trading signals, few indicators are as closely tracked as the Relative Strength Index (RSI). A stock's RSI measures the speed and magnitude of its recent price movements. marketbeat.com - 1 month ago
Why The Cooper Companies (COO) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 1 month ago
Understanding The Cooper Companies (COO) Reliance on International Revenue Explore The Cooper Companies' (COO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock. zacks.com - 1 month ago
COO Q2 Earnings Signal Growth and Caution: How to Play the Stock? Cooper Companies COO delivered a solid fiscal second quarter performance in 2025, surpassing analyst expectations with $1 billion in revenue (up 6.3% YoY) and adjusted earnings per share (EPS) of 96 cents (up 14% YoY). Despite persistent macroeconomic headwinds and a slightly softened outlook for industry growth, management reaffirmed confidence in its core product momentum and operational leverage. zacks.com - 1 month ago
XRAY vs. COO: Which Stock Should Value Investors Buy Now? Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Dentsply International (XRAY) or The Cooper Companies (COO). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 1 month ago
Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More U.S. equities were lower at midday as the market focused on the future of U.S.-China trade. The Dow Jones Industrial Average, S&P 500, and Nasdaq all lost ground. investopedia.com - 1 month ago
COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down COO's fiscal Q2 earnings and sales beat market expectations on the back of strong growth. Improvement in operating margin bodes well. zacks.com - 1 month ago
8. Profile Summary

The Cooper Companies, Inc. COO

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 14.6 B
Dividend Yield 0.00%
Description The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Contact 6101 Bollinger Canyon Road, San Ramon, CA, 94583 https://www.coopercos.com
IPO Date Jan. 21, 1983
Employees 16000
Officers Mr. Gerard H. Warner III President of CooperVision, Inc. Ms. Holly R. Sheffield President of CooperSurgical, Inc. Mr. Kim Duncan Vice President of Investor Relations & Risk Management Mr. Nicholas S. Khadder J.D. Vice President, General Counsel & Corporate Secretary Mr. Albert G. White III President, Chief Executive Officer & Non-Independent Director Mr. Brian G. Andrews Executive Vice President, Chief Financial Officer & Treasurer Mr. Daniel G. McBride Esq. Executive Vice President & Chief Operating Officer Mr. Agostino Ricupati CPA Senior Vice President & Chief Accounting Officer